CD151 gene and protein expression provides independent prognostic information for patients with adenocarcinoma of the esophagus and gastroesophageal junction treated by esophagectomy

Background: Esophageal and gastroesophageal junctional (GEJ) adenocarcinoma is one of the most fatal cancers and has the fastest rising incidence rate of all cancers. Identification of biomarkers is needed to tailor treatments to each patient’s tumor biology and prognosis. Methods: Gene expression profiling was performed in a test cohort of 80 chemoradiotherapy (CRTx)-naive patients with external validation in a separate cohort of 62 CRTx-naive patients and 169 patients with advanced-stage disease treated with CRTx. Results: As a novel prognostic biomarker after external validation, CD151 showed promise. Patients exhibiting high levels of CD151 (Cmedian) had a longer median overall survival than patients with low CD151 tumor levels (median not reached vs. 30.9 months; p = 0.01). This effect persisted in a multivariable Cox-regression model with adjustment for tumor stage [adjusted hazard ratio (aHR), 0.33; 95 % confidence interval (CI), 0.14–0.78; p = 0.01] and was further corroborated through immunohistochemical analysis (aHR, 0.22; 95 % CI, 0.08–0.59; p = 0.003). This effect was not found in the separate cohort of CRTx-exposed patients. Conclusion: Tumoral expression levels of CD151 may provide independent prognostic information not gained by conventional staging of patients with esophageal and GEJ adenocarcinoma treated by esophagectomy alone.